Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2M | 2M | 2M | 2M | 1M |
| Gross Profit | 2M | 2M | 2M | 1M | 963K |
| Operating Income | 267K | -1M | -686K | -15K | -86K |
| EBITDA | 475K | -1M | -453K | 179K | -62K |
| Net Income | 302K | -2M | -1M | -28K | -87K |
| EPS (Diluted) | — | — | — | — | — |
Consumer Defensive
Live Price
Offline$2.02
+0.00% today
1Y Change
+1.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zhong Yuan Bio-Technology Holdings Limited (ZHYBF) is a Consumer Defensive stock with a market cap of $40.00M and listed on OTC. The stock last traded around $2.02 and up 1.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +37.0%, EPS growth of +114.2%, a dividend yield of 0.0%. What stands out right now is revenue +37.0%, EPS +114.2%, free cash flow +27.0% with operating margin 11.7% and ROIC 10.1%. Valuation already assumes a fairly strong business story at P/E 118.6 and price/sales 15.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZHYBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZHYBF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZHYBF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZHYBF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2M
-25.4% YoY
FY Net Income
-$87.3K
-211.5% YoY
Free Cash Flow
-$154.1K
-150.8% YoY
Revenue Growth
+37.0%
EPS Growth
+114.2%
Gross Margin
90.9%
Net Margin
13.3%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2M | 2M | 2M | 2M | 1M |
| Gross Profit | 2M | 2M | 2M | 1M | 963K |
| Operating Income | 267K | -1M | -686K | -15K | -86K |
| EBITDA | 475K | -1M | -453K | 179K | -62K |
| Net Income | 302K | -2M | -1M | -28K | -87K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 145K | 278K | 101K | 195K | 61K |
| Total Assets | 3M | 2M | 3M | 3M | 2M |
| Total Liabilities | 3M | 3M | 2M | 2M | 800K |
| Shareholder Equity | -205K | -347K | 941K | 2M | 1M |
| Total Debt | 3M | 2M | 2M | 2M | 724K |
| Net Debt | 2M | 2M | 2M | 2M | 663K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
147K
-147.4% YoY
Capital Expenditures
8K
-34.4% YoY
Free Cash Flow
154K
-150.8% YoY
Key ratios
Gross Margin
90.9%
Operating Margin
11.7%
Net Margin
13.3%
ROE
-109.7%
Debt / Equity
-12.80x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.